← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #531 OF 1,000 MOST-CITED

Manufacturing Instructions and Specifications

FDA cited this observation 35 times across 35 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs35
BY FISCAL YEAR
FY20254
FY20244
FY20232
FY20223
FY20213
FY20201
FY20194
FY201810
FY20174

How FDA worded it — real examples

The master production and control records are deficient in that they do not include complete manufacturing and control instructions, specifications, special notations and precautions to be followed.

BSO, LLC · Golden, Colorado · Drugs · 2025-06-27

The master production and control records are deficient in that they do not include complete manufacturing, instructions and procedures.

Innocore Sales & Marketing Inc. · Woodstock · Drugs · 2025-04-25

The master production and control records are deficient in that they do not include complete manufacturing, control, instructions and specifications.

KVK Tech, Inc. · Newtown, Pennsylvania · Drugs · 2025-03-14

The master production and control records are deficient in that they do not include complete manufacturing, instructions, sampling, procedures and specifications.

Taizhou Kangping Medical Science And Technology Co., Ltd. · Taizhou · Drugs · 2025-03-14

The master production and control records are deficient in that they do not include complete manufacturing, control, instructions, sampling, testing, procedures, specifications, special notations and precautions.

BOSTON NUTRACEUTICAL PRODUCTION, S.L. · Valladolid · Drugs · 2024-06-14

The master production and control records are deficient in that they do not include complete instructions and procedures.

Tecnocosmesi S.p.A. · Massalengo · Drugs · 2024-05-10

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →